Bank of America’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.6M | Buy |
415,483
+361,664
| +672% | +$9.64M | ﹤0.01% | 2776 |
|
|
2025
Q4 | $1.55M | Buy |
53,819
+11,054
| +26% | +$144K | ﹤0.01% | 4258 |
|
|
2025
Q3 | $308K | Sell |
42,765
-25,984
| -38% | -$191K | ﹤0.01% | 6065 |
|
|
2025
Q2 | $683K | Sell |
68,749
-41,307
| -38% | -$436K | ﹤0.01% | 5537 |
|
|
2025
Q1 | $1.04M | Sell |
110,056
-60,487
| -35% | -$840K | ﹤0.01% | 5185 |
|
|
2024
Q4 | $2.35M | Buy |
170,543
+154,127
| +939% | +$2.7M | ﹤0.01% | 4312 |
|
|
2024
Q3 | $250K | Sell |
16,416
-121
| -0.7% | -$599 | ﹤0.01% | 5900 |
|
|
2024
Q2 | $78.9K | Sell |
16,537
-5,465
| -25% | -$30.5K | ﹤0.01% | 6355 |
|
|
2024
Q1 | $149K | Sell |
22,002
-1,726
| -7% | -$8.35K | ﹤0.01% | 6040 |
|
|
2023
Q4 | $116K | Buy |
23,728
+8,989
| +61% | +$29.3K | ﹤0.01% | 6317 |
|
|
2023
Q3 | $50.4K | Buy |
14,739
+5,995
| +69% | +$33.7K | ﹤0.01% | 6506 |
|
|
2023
Q2 | $41.8K | Buy |
8,744
+7,344
| +525% | +$32.3K | ﹤0.01% | 6518 |
|
|
2023
Q1 | $5.91K | Buy |
1,400
+1,371
| +4,728% | +$5.9K | ﹤0.01% | 7033 |
|
|
2022
Q4 | $112 | Sell |
29
-3,471
| -99% | -$16.6K | ﹤0.01% | 7651 |
|
|
2022
Q3 | $21K | Sell |
3,500
-1,500
| -30% | -$7.67K | ﹤0.01% | 7005 |
|
|
2022
Q2 | $17K | Buy |
+5,000
| New | +$17.7K | ﹤0.01% | 7225 |
|
|
2021
Q4 | – | Sell |
-337
| Closed | -$1K | – | 8240 |
|
|
2021
Q3 | $1K | Buy |
337
+327
| +3,270% | +$1.49K | ﹤0.01% | 7964 |
|
|
2021
Q2 | $0 | Buy |
+10
| New | +$42 | ﹤0.01% | 7763 |
|
|
2020
Q3 | – | Sell |
-13
| Closed | – | – | 6903 |
|
|
2020
Q2 | $0 | Sell |
13
-237
| -95% | -$1.03K | ﹤0.01% | 6836 |
|
|
2020
Q1 | $0 | Hold |
250
| – | – | ﹤0.01% | 6864 |
|
|
2019
Q4 | $0 | Sell |
250
-27
| -10% | -$56 | ﹤0.01% | 7097 |
|
|
2019
Q3 | $1K | Sell |
277
-323
| -54% | -$1.12K | ﹤0.01% | 7080 |
|
|
2019
Q2 | $2K | Buy |
600
+346
| +136% | +$1.45K | ﹤0.01% | 6948 |
|
|
2019
Q1 | $1K | Sell |
254
-296
| -54% | -$1.52K | ﹤0.01% | 6963 |
|
|
2018
Q4 | $2K | Sell |
550
-83
| -13% | -$659 | ﹤0.01% | 6891 |
|
|
2018
Q3 | $7K | Buy |
633
+83
| +15% | +$989 | ﹤0.01% | 6748 |
|
|
2018
Q2 | $7K | Hold |
550
| – | – | ﹤0.01% | 6734 |
|
|
2018
Q1 | $7K | Sell |
550
-100
| -15% | -$1.74K | ﹤0.01% | 6693 |
|
|
2017
Q4 | $10K | Buy |
650
+250
| +63% | +$5.41K | ﹤0.01% | 6600 |
|
|
2017
Q3 | $12K | Buy |
400
+100
| +33% | +$1.2K | ﹤0.01% | 6470 |
|
|
2017
Q2 | $2K | Sell |
300
-4
| -1% | -$73 | ﹤0.01% | 6736 |
|
|
2017
Q1 | $10K | Buy |
304
+4
| +1% | +$111 | ﹤0.01% | 6534 |
|
|
2016
Q4 | $8K | Buy |
300
+55
| +22% | +$1.65K | ﹤0.01% | 6602 |
|
|
2016
Q3 | $8K | Buy |
245
+192
| +362% | +$7.22K | ﹤0.01% | 6452 |
|
|
2016
Q2 | $2K | Buy |
53
+3
| +6% | +$106 | ﹤0.01% | 6884 |
|
|
2016
Q1 | $1K | Buy |
+50
| New | +$1.21K | ﹤0.01% | 6851 |
|
Other funds holding CAPR
SCM
TCM
VCM
RCM
JHC
Bank of America's CAPR Position: Q1 2026 in Review
Bank of America increased its Capricor Therapeutics (CAPR) stake by 672% in Q1 2026, buying an estimated $9.64M and bringing the position to 415,483 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2776.
Bank of America first reported a position in CAPR in Q1 2016 and has held it in 36 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.
- Bank of America held 415,483 shares of Capricor Therapeutics worth $12.6M as of Q1 2026.
- Bank of America bought 361,664 Capricor Therapeutics shares in Q1 2026, an estimated $9.64M.
- Capricor Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2776 holding.
- Bank of America first reported a position in Capricor Therapeutics in Q1 2016 and has held it in 36 quarters since.
- 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.